FindTrial
Sign In

Study for Optimizing Individualized Administration of Tacrolimus in Infant Liver Transplant Recipients

Study for Optimizing Individualized Administration of Tacrolimus in Infant Liver Transplant Recipients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031002
Enrollment
Unknown
Registered
2020-03-20
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Interventions

modeling group vs model validation group:N/A

Sponsors

Tianjin First Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 3 Years

Inclusion criteria

Inclusion criteria: 1. All the recipients were <=3 years old at the time of liver transplantation; 2. Tacrolimus-based immunosuppressive regimens were used post transplantation; 3. Postoperative survival was more than 3 months.

Exclusion criteria

Exclusion criteria: 1. Take tacrolimus for less than 3 months or change immunosuppressive regimen halfway through; 2. Occurrence of serious complications or death within 3 months post transplantation; 3. The patient's clinical information and data are seriously missing.

Design outcomes

Primary

MeasureTime frame
Clinical;Biochemical index;Single nucleotide gene polymorphism;Prognostic information;—

Countries

China

Contacts

Public ContactYinpeng Qin

Tianjin First Central Hospital

hebgcqx@163.com+86 022 23627195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026